Skip to main content

View full-text article in PMC

. 2013 Oct 25;2(5):e000136. doi: 10.1161/JAHA.113.000136

Table 5.

Risk of Recurrent Venous Thromboembolism With Target‐Specific Anticoagulants Versus Conventional Therapy

Randomized Clinical Trial	Number of Events/Total		Risk Ratio (95% CI)
Randomized Clinical Trial	TSOA	LMWH+VKA	Risk Ratio (95% CI)
Dabigatran
RECOVER I⁶⁸	30/1274	27/1265	1.10 (0.66 to 1.84)
RECOVER II⁶⁹	30/1279	28/1289	1.08 (0.65 to 1.8)
Rivaroxaban
EINSTEIN‐DVT⁶⁶	36/1731	51/1718	0.70 (0.46 to 1.07)
EINSTEIN‐PE⁶⁷	50/2419	44/2413	1.13 (0.76 to 1.69)
Apixaban
AMPLIFY⁷⁰	59/2609	71/2635	0.84 (0.60 to 1.18)

LMWH indicates low‐molecular‐weight heparin; TSOA, target‐specific oral anticoagulant; VKA, vitamin K antagonist.